Abu Dhabi Stem Cells Center (ADSCC) and Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare services provider in MENA listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), have recently announced a strategic partnership.
According to Industry sources, this partnership will expand bone marrow transplant and cellular therapy in the Group’s flagship facility, Burjeel Medical City (BMC). This partnership focuses on boosting access to advanced care for adult and pediatric patients with blood cancer, genetic diseases, autoimmune diseases, and others.
Industry sources further confirmed that this strategic initiative will directly pave way for an extensive, integrated ecosystem for advanced research and cellular therapy, and further reinforce Abu Dhabi’s status as a global healthcare destination.
Furthermore, Industry sources quickly added that ADSCC will extend its proprietary Abu Dhabi Bone Marrow Transplant Program (AD-BMT©) to BMC. Accredited as the Center of Excellence in Hematopoietic Stem Cell Transplantation by the Department of Health – Abu Dhabi, ADSCC strictly adheres to the best global practices based on scientific evidence and is one of best in the UAE and one of only two centers in the Middle East to be recognized by the Foundation for the Accreditation of Cellular Therapy (FACT), the leading accreditation organization for cellular therapy programs on a global scale.
ADSCC and BMC have extensive capabilities in bone marrow transplants/hematopoietic stem cell transplantation, cellular therapy, and the management of various benign hematological disorders in adult and pediatric patients, including thalassemia, rare genetic disorders, and sickle cell disease.
